
Mira 25 Tablet ER
Marketer
Lupin Ltd
Salt Composition
Mirabegron (25mg)
Overview Mira 25 Tablet ER
Mira 25 Extended-Release tablets manage overactive bladder symptoms like frequent urination, urgency, and incontinence. This medication relaxes bladder muscles, improving urine storage capacity. Always follow your doctor's prescribed dosage and duration; it can be taken with or without food. Swallow the tablet whole – do not crush or chew. Discontinuing treatment prematurely may worsen symptoms; complete the prescribed course for optimal results. Potential side effects include constipation, headache, hypertension, nasal congestion, urinary tract infection, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your physician immediately. Before starting treatment, disclose all other medications and pre-existing health conditions, including pregnancy or breastfeeding. Patients with hepatic or renal impairment should exercise caution and undergo regular monitoring as directed by their doctor.
Uses of Mira 25 Tablet ER
Managing symptoms associated with overactive bladder
Major Benefits of Mira 25 Tablet ER:
Administer this medication precisely as directed by your physician, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Mira 25 Extended-Release Tablets can be consumed with or without food, though consistent timing is recommended.
Common Side effects of Mira 25 Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use Mira 25 Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Mira 25 Extended-Release Tablets can be consumed with or without food, although consistent timing is recommended.
How Mira 25 Tablet ER works:
Extended-release Mira 25 tablets contain a beta-3 adrenergic agonist that acts on bladder receptors. This activation promotes bladder muscle relaxation, thereby reducing urinary urgency, frequency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when combining Mira 25 Tablet ER and alcohol. Seek medical advice before doing so.
PregnancyCONSULT YOUR DOCTOR
Extended-release Mira 25 tablets might pose pregnancy risks. While human research is scant, animal studies indicate potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Mira 25 tablets are likely unsafe for breastfeeding mothers. Available evidence from humans indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Mira 25 Extended-Release Tablets.
KidneyCAUTION
Extended-release Mira 25 tablets require careful administration for individuals with advanced kidney impairment. Dosage modification of Mira 25 ER may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use Mira 25 Extended-Release tablets cautiously, potentially requiring dosage modification under medical supervision. Mira 25 Extended-Release tablets are contraindicated in patients with severe hepatic dysfunction.
What if you forget to take Mira 25 Tablet ER :
Should you forget a Mira 25 Tablet ER dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed one and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Mira 25 Tablet ER
| Label | Value |
|---|---|
| Chemical Category | Anilide-based compound |
| Developing Habits | No. |
| Treatment Category | Urological Care |
| Actions | Selective beta-3 adrenergic agonist (for bladder) |
